Alzheimer’s disease is a progressive brain disorder that slowly destroys memory, thinking skills, and eventually the ability to carry out basic daily tasks. It is the most common cause of dementia, accounting for the majority of cases, and currently affects an estimated 49 million people aged 65 and older worldwide. That number is projected to reach 152 million by 2050. In the United States alone, Alzheimer’s causes over 116,000 deaths per year, making it one of the top causes of death in the country.
What Happens in the Brain
Alzheimer’s involves two proteins that go wrong: amyloid-beta and tau. In a healthy brain, amyloid-beta exists at low levels and actually supports normal brain function, including memory formation. But in Alzheimer’s, amyloid-beta accumulates to toxic concentrations and clumps together into sticky plaques between nerve cells. These plaques trigger a chain reaction inside neurons. They activate an enzyme that causes tau, a protein normally responsible for stabilizing the internal structure of brain cells, to become chemically altered. The altered tau twists into tangled fibers inside neurons, destroying the cell’s transport system.
Together, plaques and tangles disrupt the connections between brain cells, change cell shape, and eventually kill neurons outright. This damage typically starts in the hippocampus, the region responsible for forming new memories, which is why short-term memory loss is almost always the earliest symptom. Over years, the destruction spreads to other brain regions that control language, reasoning, spatial awareness, and eventually basic body functions like swallowing and bladder control.
Early Symptoms and How They Progress
Alzheimer’s unfolds in three broad stages, though the pace varies widely from person to person. The entire course from first symptoms to end of life typically spans 4 to 8 years but can stretch beyond a decade.
Mild Stage
The earliest signs are often mistaken for normal aging. You or a loved one might notice repeated questions, trouble keeping track of dates, difficulty handling money or paying bills, and taking longer than usual to complete routine tasks. Poor judgment and bad decisions start to stand out. Things get misplaced in odd locations. There may be a loss of motivation or initiative, along with growing anxiety or irritability. At this stage, most people can still live independently, but the problems are noticeable to family and close friends.
Moderate Stage
This is typically the longest stage and brings significant changes. Memory loss deepens to the point of forgetting personal history or major life events. Learning new information becomes nearly impossible. Language breaks down: reading, writing, and working with numbers all become difficult. Familiar multistep tasks like getting dressed require help. Sleep patterns shift, often with increased daytime napping and nighttime restlessness. Some people experience hallucinations, paranoia, or emotional outbursts. Recognizing family members becomes inconsistent. Wandering, especially in the late afternoon or evening (sometimes called “sundowning”), is common and a major safety concern.
Severe Stage
In the final stage, the person loses the ability to communicate, respond to their surroundings, or control movement. Swallowing becomes difficult, leading to weight loss and increased risk of infections like pneumonia. Bowel and bladder control is lost. The body undergoes a general physical decline. Most people in this stage require around-the-clock care.
Risk Factors and Genetics
Age is the single biggest risk factor. The vast majority of Alzheimer’s cases occur in people over 65, and risk roughly doubles every five years after that. But age alone doesn’t cause it. A combination of genetics, lifestyle, and environmental factors all contribute.
The strongest known genetic risk factor for late-onset Alzheimer’s is a gene variant called APOE e4. Everyone inherits two copies of the APOE gene, one from each parent, and the e4 version significantly raises risk. Carrying one copy of APOE e4 doubles or triples your risk of developing Alzheimer’s. Carrying two copies increases the risk 8 to 12 times compared to people without the variant. That said, many people with APOE e4 never develop the disease, and many people without it do. It is a risk factor, not a diagnosis.
Rare, inherited forms of Alzheimer’s are caused by mutations in specific genes and can strike as early as a person’s 30s or 40s. These familial cases account for a very small percentage of all Alzheimer’s diagnoses. Other factors that increase risk include cardiovascular disease, diabetes, obesity, head injuries, chronic sleep deprivation, social isolation, and lower levels of education or cognitive engagement throughout life.
How It’s Diagnosed
For years, the only definitive way to confirm Alzheimer’s was through an autopsy. Doctors could make a clinical diagnosis based on cognitive testing, brain imaging, and ruling out other causes, but detecting the actual amyloid plaques in a living person required expensive PET brain scans or a spinal tap to analyze cerebrospinal fluid. Both are invasive, costly, or not widely available.
That changed recently with the first FDA-cleared blood test for Alzheimer’s. The test measures a specific ratio of proteins in the blood (a form of tau and a fragment of amyloid) and matches the accuracy of those more invasive methods remarkably well. In clinical studies, 91.7% of people who tested positive on the blood test were confirmed to have amyloid plaques by PET scan or spinal fluid analysis. Among those who tested negative, 97.3% were confirmed negative. This kind of simple, accessible screening has the potential to identify the disease much earlier and in many more people.
Treatment Options
There is no cure for Alzheimer’s, but the treatment landscape has shifted meaningfully in recent years. Older medications can temporarily ease symptoms by boosting chemical signaling between surviving brain cells, helping with memory and thinking for a period of months to a couple of years. They don’t slow the underlying disease.
A newer class of treatments takes a different approach by targeting amyloid plaques directly. These are antibody-based drugs given by IV infusion that bind to amyloid and help the brain clear it. One such treatment, donanemab (sold as Kisunla), received FDA approval after a clinical trial showed it significantly slowed cognitive and functional decline compared to placebo over 76 weeks. Once brain scans confirmed a patient’s amyloid levels had dropped below a certain threshold, treatment was stopped, which is a notable difference from drugs that require indefinite use. Lecanemab (Leqembi) works through a similar mechanism and was approved earlier.
These drugs carry real risks, including brain swelling and small brain bleeds, which require regular monitoring with MRI scans. They are most effective in people with early-stage disease, and the degree of slowing, while statistically significant, is modest. For some patients, it may translate into several additional months of independent living. For others, the risks and burdens of treatment may not be worth the benefit. These are decisions best made individually, with a thorough understanding of where a person falls in the disease.
What Reduces Risk
Because so many risk factors for Alzheimer’s overlap with cardiovascular health, the same habits that protect your heart appear to protect your brain. Regular aerobic exercise, even moderate-intensity walking, is one of the most consistently supported strategies. Managing blood pressure, blood sugar, and cholesterol in midlife all appear to lower dementia risk decades later.
Staying socially connected, getting consistent quality sleep, treating hearing loss, and continuing to challenge your brain with new learning all show protective associations in large population studies. No single habit guarantees prevention, but the cumulative effect of these factors is substantial. Some researchers estimate that up to 40% of dementia cases worldwide could theoretically be prevented or delayed by addressing modifiable risk factors across a lifetime.